Novo Nordisk Bets on AI Acceleration, EU Backing for Oral Wegovy, and Liver Data to Reignite Its Story

Novo Nordisk leverages AI to slash regulatory preparation by two-thirds, while presenting pivotal MASH liver disease data and advancing oral obesity pill in Europe.

Novo Nordisk is racing to compress the journey from clinical trial to pharmacy shelf, using artificial intelligence to slash regulatory preparation times by as much as two-thirds. The Danish drugmaker’s push comes as it prepares to unveil pivotal liver-disease data in Barcelona this week, while fresh European regulatory support for its oral obesity pill adds another near-term catalyst.

The company has already cut the typical 18-month gap between a study’s conclusion and regulatory submission to just a few months, thanks to AI systems that automate the drafting of dossiers and analyse safety data. Much of this work is handled at Novo Nordisk’s global service centre in Bengaluru, India, which is set to expand to roughly 4,000 employees by the end of 2026. The hiring focus will be squarely on specialised AI roles rather than general headcount growth.

That speed is crucial as Novo Nordisk moves to capitalise on the European Medicines Agency’s human medicines committee (CHMP) backing for the first oral GLP-1 treatment for obesity – the Wegovy pill – along with a new 7.2 mg single-dose pen. The company aims to bring both products to European markets as quickly as possible, and the AI initiative is designed to accelerate the post-approval launch process.

Liver Disease Data Take Centre Stage

All eyes now turn to the EASL International Liver Congress in Barcelona, running from 27 to 30 May. Novo Nordisk will present detailed results from the ESSENCE phase 3 programme, evaluating semaglutide’s effect on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver condition that affects an estimated 250 million people worldwide and can progress to fibrosis, cirrhosis, liver failure, or cancer.

The 2.4 mg dose of semaglutide has already shown meaningful reductions in liver inflammation and fibrosis in MASH patients. New safety data will aim to reinforce the drug’s hepatic profile, while subgroup analyses – including data on Japanese patients and postmenopausal women – could broaden the commercial case. With nine out of ten MASH cases currently undiagnosed, a robust dataset across diverse populations would open a sizeable new indication beyond diabetes and obesity.

Market Under Pressure Despite Recent Stabilisation

The strategic push has yet to fully register in the share price. Novo Nordisk’s stock closed Friday at €38.74, up 1.25% on the day but still almost 45% below its 52-week high of €70.13. Year-to-date losses stand at roughly 13%, though the stock has rebounded more than 16% over the past month and now trades 11.52% above its 50-day moving average – a technical signal that short-term momentum is improving. It remains 8.17% below its 200-day line, indicating the longer-term downtrend has not fully reversed.

A share buyback programme running in the background provides additional support. Announced on 4 February 2026, the plan allows for repurchases of up to 15 billion Danish kroner over 12 months. The B-share tranche, which runs from 6 May 2026 to 1 February 2027, is capped at 11.2 billion kroner. As of 13 May, Novo had bought back 15,999,028 B-shares at an average price of 260.62 kroner apiece, for a total of 4.17 billion kroner. The company now holds 33,184,329 own B-shares, equivalent to 0.7% of total share capital.

What’s Next: ADA, CagriSema, and a Packed Calendar

After Barcelona, the next major event on the calendar is the American Diabetes Association congress in New Orleans, starting 5 June. Two days later, Novo Nordisk will host an R&D investor event where its broader obesity pipeline is expected to take top billing. Already confirmed is a presentation on CagriSema, examining its effects on appetite and functional brain activity in people with overweight and obesity – part of the company’s strategy to extend its GLP-1 franchise beyond Wegovy.

The oral Wegovy pill continues to build momentum: it reached roughly 1.3 million prescriptions in its first three months, and outside the US the company now targets a launch in the second half of 2026, pending regulatory approvals. First-quarter results underline the underlying strength – currency-adjusted revenues rose 32% to 96.8 billion Danish kroner ($15.2 billion on a reported basis).

Investors will also have the half-year figures on 5 August and a Capital Markets Day on 21 September to look forward to. For now, the EASL data from Barcelona will determine whether Novo Nordisk can add a lucrative new chapter to its growth story – and whether the stock’s recent technical recovery can be sustained.